High-dimensional analysis reveals baricitinib reduces immune dysregulation and enhances MDSCs in multirefractory ITP patients, indicating therapeutic promise.
Key Points
To identify unique immune signatures and therapeutic targets in multirefractory immune thrombocytopenia (ITP) patients.
Conducted mass cytometry analysis on peripheral blood mononuclear cells from 27 individuals, including MR and non-MR ITP patients and healthy controls.
Applied unsupervised clustering algorithms and dimensionality reduction techniques to assess immune cell populations.
Monitored immune cell changes post-baricitinib treatment over 12 weeks.
Identified a distinct immune signature in multirefractory patients characterized by expanded cytotoxic γδT cells and reduced myeloid-derived suppressor cells.
Baricitinib treatment led to a 64% reduction of pathogenic γδT cells and significant restoration of regulatory myeloid cells.
Treatment correlated with improved platelet counts, reflecting a broader reestablishment of immune homeostasis.